Company

TaiRx, Inc.

Headquarters: Taipei City, Taiwan

CEO: Dr. Chien Du-Shieng Ph.D.

TWSE: 6580 +0.51%

Market Cap

TW$4.25 Billion

TWD as of July 1, 2024

US$130.5 Million

Market Cap History

TaiRx, Inc. market capitalization over time

Evolution of TaiRx, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of TaiRx, Inc.

Detailed Description

TaiRx, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial; and Rexis, an add-on injection therapy that is in Phase III clinical trials to treat patients with sepsis. Its pre-clinical products comprise TRX-711 that is used to treat secondary hyperparathyroidism; TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in patient's blood Se level and immune system; and focuses on development of the nodal diagnostic devices and anti-body drugs. TaiRx, Inc. was founded in 2011 and is based in Taipei City, Taiwan.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

TaiRx, Inc. has the following listings and related stock indices.


Stock: TWSE: 6580 wb_incandescent

Details

Headquarters:

No. 66, San-Chung Road

6th Floor-1 Nankang Business Park

Taipei City, 11502

Taiwan

Phone: 886 2 2653 5007

Fax: 886 2 2653 5008